Hilar cholangiocarcinoma patient prognosis prediction model

A cholangiocarcinoma and patient technology, which is applied in the field of prognosis prediction models for patients with hilar cholangiocarcinoma, can solve the problems of unsatisfactory patient prognosis prediction, complex scoring system, and not widely promoted clinical applications.

Pending Publication Date: 2017-10-31
SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI +1
View PDF0 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this staging does not take into account risk factors affecting prognosis such as hepatic artery invasion and surgical resection results (R0 resection, R1 resection, and R2

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hilar cholangiocarcinoma patient prognosis prediction model
  • Hilar cholangiocarcinoma patient prognosis prediction model
  • Hilar cholangiocarcinoma patient prognosis prediction model

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0317] 1. Experimental steps

[0318] 1.1 Population screening

[0319] Firstly, the clinical information of patients with non-metastatic hilar cholangiocarcinoma diagnosed and treated in Dongfang Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University from 2000 to 2009 was retrospectively analyzed to construct a prognostic model. Patients with intrahepatic cholangiocarcinoma, distal cholangiocarcinoma, metastatic cholangiocarcinoma, and undiagnosed tumors were excluded; patients with liver cancer invading the hilar cholangiocarcinoma and patients with hilar cholangiocarcinoma who could not receive surgery were excluded (Bismuth Stage IV, or Bismuth IIIa and IIIb patients with absolute contraindications for contralateral portal vein invasion); patients who died of surgical complications 1 month after surgery were also excluded. 235 patients with hilar cholangiocarcinoma who met the inclusion criteria became the training set for constructing the prognos...

Embodiment 2

[0346] Will figure 1 The nomogram is scaled up in equal proportions and printed on A4 paper with a common printer to obtain the card of this embodiment.

Embodiment 3

[0348] Will figure 1 The nomogram is scaled up in equal proportions, and printed on an A4-sized PVC sheet with a conventional printing machine to obtain a plastic material card.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a prognosis prediction model for patients with hilar cholangiocarcinoma. Specifically, the present invention provides a carrier for postoperative prognosis of patients with hilar cholangiocarcinoma, which is used to calculate risk factor scores and patient 3-year survival rate Y3 and/or 5-year survival rate Y5; Wherein, the risk factors include at least the patient's age X, and the fraction of the patient's age, the 3-year survival rate and the 5-year survival rate satisfy the relationship described in the article. The present invention systematically investigates the clinical and pathological characteristics that affect the prognosis of patients with hilar cholangiocarcinoma, and the effect of patients after surgical treatment, evaluates the key factors that affect the survival and prognosis of patients with hilar cholangiocarcinoma, and establishes a method for patients with hilar cholangiocarcinoma. The list of survival prognosis is used to evaluate the 3-year and 5-year survival rate of patients after surgery, and to screen out high-risk groups for intervention to improve the survival prognosis of patients.

Description

technical field [0001] The invention relates to a prognosis prediction model for patients with hilar cholangiocarcinoma. Background technique [0002] Cancer antigen CA19-9 is a tumor marker related to pancreatic cancer, cholangiocarcinoma, gallbladder cancer, colon cancer and gastric cancer, also known as gastrointestinal tract-associated antigen. It is sialylated lacto-N-fucopentose II, which is a mucinoid glycoprotein component, related to the hapten of the Lewis blood group component, with a molecular weight of 1 million to 5 million. Cancer antigen CA19-9 has high sensitivity and good specificity to pancreatic cancer, and its positive rate is between 85% and 95%, and it decreases with the improvement of the condition after operation. At present, the cancer antigen CA19-9 is mainly used for the diagnosis and monitoring of tumor recurrence in the above-mentioned digestive tract tumors, but its prognostic value for cholangiocarcinoma has not yet been fully clarified. [...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G06F19/00
Inventor 王慧姜小清李斌陈培战朱焱
Owner SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap